Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program

Company sees both the Activator program (autoimmune disorders) and the Inhibitor program (immunotherapy for cancer treatment) as major markets for its small molecule drug development.

Jun 16, 2016, 08:00 ET from Regen BioPharma Inc.

SAN DIEGO, June 16, 2016 /PRNewswire/ --

Regen BioPharma, Inc., (OTCQB: RGBP and OTCQB: RGBPP) recently announced that it has identified small molecules that activate the Company's newly identified immune checkpoint, NR2F6.  This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.  

"In autoimmune diseases the immune system, for unknown reasons, is highly active against normal tissue.  The activators we have identified should interfere with this autoimmune process.  The production of some of the key molecules that activate the immune system are controlled by NR2F6.  In experiments which will be performed in the near future, we expect our compounds to stop production of these immune-activating molecules," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.

"Small molecule therapy is very similar in scope to taking an antibiotic pill for treating an infection.  Regen is focused on creating oral small molecule drugs that will be used to treat cancer, arthritis and other autoimmune maladies.  This approach is believed to be more cost effective, less traumatic for the patient and provide a higher level of efficacy in treatment," said David Koos, Ph.D., Chairman and CEO of Regen.

Mr. Koos further stated "There are many diseases where a person's own immune system attacks their own body. These diseases are called autoimmune disorders and there are more than 100 known types.  Some well-known ones are rheumatoid arthritis, lupus, Crohn's disease, and multiple sclerosis.  Although there are currently some treatments for these, none are very effective.  The annual cost of treatment for the top seven autoimmune disorders is estimated to be between $50 - 70 billion[1],[ 2] . We believe both our activator program (for treatment of autoimmune disorders) and our inhibitor program (for treatment of cancer utilizing immunotherapy) will provide major markets for Regen's small molecule drug development."

About Regen BioPharma, Inc. 

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:

Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Phone: +1-619-702-1404
Fax: +1-619-330-2328 Fax
David.koos@regenbiopharma.com

The Dorsee Company
Debra Dorsee
+1-858-229-6082
Debbie@thedorseecompany.com

http://www.regenbiopharma.com
http://www.regenbiopharmainc.com
Twitter:  Regen BioPharma News:
https://twitter.com/RegenBioPharm

 

[1] http://www.fortressbiotech.com/research-development/autoimmune-therapeutics-market.cfm

[2] http://www.statista.com/statistics/312349/worldwide-inflammation-and-autoimmunity-therapy-market-by-condition/

SOURCE Regen BioPharma Inc.